Tenon Medical, Inc. (TNON) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's strong Q1 performance, with a 90% revenue increase and significant gross margin improvement, is encouraging. Positive sentiments from management and analysts, along with upcoming product launches and a sustainable high gross margin, suggest a positive outlook. Despite risks like operating expenses and convertible note financing, the overall sentiment is positive, supported by optimistic guidance and strategic initiatives.
Key Financial Performance
First Quarter Revenue $1.4 million, an increase of approximately 90% year-over-year from $0.7 million. Growth driven by strong Catamaran surgical procedure volumes and the first full quarter of SImmetry+ revenue since acquisition.
Gross Margin 68.5%, up from 44.5% a year ago, representing a 24 percentage point increase. Improvement attributed to higher revenue spreading fixed production costs over a larger base and a more streamlined commercial footprint.
Gross Profit $0.9 million, a 193% increase year-over-year from $0.3 million. Growth driven by increased revenue and improved cost absorption.
Operating Expenses $4.2 million, slightly up from $4.0 million in Q1 2025. Increase due to higher sales and marketing expenses for SImmetry+ rollout, partially offset by lower stock-based compensation.
Net Loss $3.5 million or $0.31 per share, narrowed from $3.6 million or $1.01 per share a year ago. Improvement due to stronger revenue and gross profit offsetting higher operating expenses and interest expense.
Cash and Cash Equivalents $4.6 million as of March 31, 2026, up from $3.8 million as of December 31, 2025. Increase supported by $4.3 million senior convertible note placement in March 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Catamaran and SImmetry+ platforms: The company reported strong growth in procedure volumes for both platforms. Catamaran cases increased significantly, and SImmetry+ had its first full quarter of meaningful contribution since its acquisition in August 2025. Further enhancements and a full commercial launch of SImmetry+ are planned for the second half of 2026.
R&D advancements: The company accelerated R&D efforts, including significant additions to the SImmetry+ lateral and oblique platform, which will launch in late 2026. A third approach to sacral pelvic anatomy is also under regulatory submission and Alpha activity.
Physician engagement and training: 21 physicians were trained across both systems in Q1 2026, indicating growing adoption and engagement.
Commercial expansion: The company added a senior sales professional to manage the eastern U.S. and established a new training and education center in Tampa, Florida, to enhance physician and distributor education.
Gross margin improvement: Gross margin increased to 68.5% in Q1 2026, up from 44.5% in Q1 2025, driven by higher revenue and improved cost efficiency.
Cost structure optimization: The company achieved a more streamlined commercial footprint and stronger field productivity, contributing to sustained operational efficiencies.
Intellectual property expansion: The company strengthened its IP portfolio with multiple notices of allowance from the U.S. Patent and Trademark Office, bringing the total to 29 U.S. patents and 9 international patents, with 31 applications pending.
Financial flexibility: A $4.3 million senior convertible note placement in March 2026 extended the company's financial runway, supporting commercial expansion, product launches, and clinical programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Dependency on New Product Launches: The company's growth strategy heavily relies on the successful commercial launch and adoption of new products like SImmetry+. Delays or underperformance in these launches could adversely impact revenue growth.
Operating Expenses: Operating expenses increased to $4.2 million, driven by higher sales and marketing costs. This could pressure profitability if revenue growth does not keep pace.
Convertible Note Financing: The company raised $4.3 million through senior convertible notes, which adds financial runway but also introduces interest expense and potential dilution risks.
Regulatory and Product Development Risks: The company is moving towards regulatory submission for new product approaches. Delays or failures in regulatory approval could hinder product launches and growth.
Market Adoption Challenges: The company’s success depends on physician adoption of its platforms. Slower-than-expected adoption rates could impact revenue and market share.
Cash Reserves: The company ended the quarter with $4.6 million in cash, which may limit its ability to fund long-term growth initiatives without additional financing.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Gross Margin: The company expects the structural gains in gross margin, which reached 68.5% in Q1 2026, to persist going forward as revenue scales.
Product Launches: Significant incremental additions to the SImmetry+ lateral and oblique platform are planned for launch in the back half of 2026. Additionally, regulatory submission and subsequent Alpha activity for a third approach to the sacral pelvic anatomy are underway.
Commercial Expansion: The company plans to continue aggressive commercial activities, including expanding procedure volumes on both Catamaran and SImmetry+ platforms, and increasing physician and distributor education through a newly established training center in Tampa, Florida.
Revenue Growth: Further product enhancements and a full commercial launch of SImmetry+ in the back half of 2026 are expected to support continued revenue growth into 2027 and beyond.
Intellectual Property: The company expects multiple patent applications to be granted later in 2026, further strengthening its intellectual property portfolio.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is it fair to be encouraged by the strong Q1 numbers despite typical seasonality challenges?
A:Steven Foster confirmed that it is fair to be encouraged by the strong Q1 numbers. He explained that deductible resets and seasonality factors are real challenges, but the company had a solid Q1 performance, which is encouraging for 2026.
Q:How should we think about Q2 relative to Q1, and are there any launch metrics to gauge progress?
A:Steven Foster outlined that 2026 will be busy with the launch of SImmetry+ and additional components throughout the year. He mentioned that the decordicator technology and an incremental implant will launch later in the year, and a new technology will enter Alpha in Q4. These launches, along with clinical data, will serve as catalysts for growth.
Q:Is Q1 OpEx a good baseline for the year, and how will it evolve?
A:Kevin Williamson stated that Q1 OpEx is a good baseline for the year. He noted that while there will be some investments, OpEx will grow at a lower rate than revenue, allowing for improved profitability and margin expansion.
Q:Can you elaborate on the new system expected to have an Alpha release in Q4 2026 and its timeline for commercialization?
A:Steven Foster explained that the new system adheres to the company's core principles of joint preparation, grafting, and fixation. It will enter Alpha in Q4 2026, with a full launch planned for Q1 2027.
Q:How has physician training evolved, and what are the plans to accelerate it?
A:Steven Foster highlighted that training has evolved due to the company's expanded technology portfolio. They have invested in a fully equipped training facility in Tampa to train physicians and distribution partners effectively.
Q:What steps are being taken to increase physician conversion rates?
A:Steven Foster stated that the company focuses on compelling physicians with technology and clinical research. They are also investing in improving approval and access processes at facilities, leveraging the SiVantage acquisition to enhance access.
Q:Is the high gross margin of 68.5% in Q1 sustainable, and what are the expectations for 2027?
A:Kevin Williamson confirmed that the high gross margin is sustainable and expected to increase as revenue scales. The company aims for margins to exceed 70% in 2027 as fixed costs are absorbed.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were detailed and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alpha
Chief Executive
Executive Officer
Financial
Mr
RD
SImmetry
Tenon Medical
acquisition
activity
adoption
afternoon
application
approach anatomy
asset
basis
center
conference
cost base
dollar
education
expansion
expense
gain
history
note
optionality
patent
percentage point
physician
placement
procedure
product launch
production
project
runway
statement
stock comp
work
TNON Transcript
Tenon Medical, Inc. (TNON) Q1 2026 Earnings Call Transcript
Positive5-13
The company's strong Q1 performance, with a 90% revenue increase and significant gross margin improvement, is encouraging. Positive sentiments from management and analysts, along with upcoming product launches and a sustainable high gross margin, suggest a positive outlook. Despite risks like operating expenses and convertible note financing, the overall sentiment is positive, supported by optimistic guidance and strategic initiatives.
Central Asia Metals plc (CAMLF) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call highlighted several concerns: a significant impairment charge, increased costs, and negative EPS. Although revenue grew, it was offset by rising costs and a substantial impairment. The Q&A revealed vague responses on cost management and future projects, adding uncertainty. The reinstated dividend policy is a positive, but overall, the financial health and guidance raise concerns. Given these factors, the sentiment is negative, suggesting a potential stock price decline of -2% to -8% in the short term.
Tenon Medical, Inc. (TNON) Q4 2025 Earnings Call Transcript
Positive3-19
The company demonstrated strong financial performance with a significant increase in both quarterly and annual revenue, driven by new product adoption. Gross margins improved, and net losses decreased, indicating operational efficiency. Despite competitive pressures, the strategic expansion of the product portfolio and positive reception of new launches like SImmetry+ suggest potential growth. The Q&A revealed management's optimism about revenue growth, despite vague guidance. The decrease in cash reserves is a concern but offset by strategic investments. Overall, the positive financial results and optimistic outlook suggest a positive stock price movement.
Tenon Medical, Inc. (TNON) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary reflects a positive sentiment with strong financial performance, particularly a 32.3% revenue increase and improved gross margins. Product development is promising with new launches, and the strategic plan indicates market expansion. Despite increased operating expenses, the net loss is slightly improved. The Q&A section suggests confidence in future growth, although some responses were vague. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.
TNON Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
